Abstract
Background: Faecal calprotectin is a non-invasive marker for neutrophilic intestinal inflammation. It can be used in the differential diagnosis between functional and organic bowel disease. Moreover, it correlates with endoscopic organic bowel disease activity. The objective of this study is to evaluate a recently launched quantitative immunochromatographic point-of-care test: Quantum Blue Calprotectin (Bühlmann Laboratories AG, Schönenbuch, Switzerland) in comparison to an established ELISA method (Bühlmann Laboratories AG).
Methods: We included 142 samples, either archived (–80°C) faecal extracts or fresh routine samples. Both the normal range cartridges as well as the high range cartridge from the point-of-care test were used. The ELISA was compared with the point-of-care test and the optimal the point-of-care test cut-off values were searched for using Microsoft® Excel 2002 and MedCalc Software version 10.0.0.0 (Mariakerke, Belgium).
Results: In the method comparison a determination coefficient (R2) of 0.89 was found. The Passing Bablok regression analysis showed a significant deviation from linearity (y=–40.8+1.0x). The use of a cut-off value of 30 μg/g faeces and a grey zone of 30–110 μg/g faeces resulted in the best agreement between the ELISA interpretation and the point-of-care test interpretation, with 89.4% (127/142) agreement and 10.6% (15/142) mismatches.
Conclusions: We may conclude that the point-of-care test can serve as a reliable alternative to the time consuming ELISA in the differential diagnosis between functional and organic bowel disease. Furthermore, it seems to be reliable in the follow-up of inflammatory bowel disease patients.
The authors would like to thank Mrs. Kristel Engelen from Alere for providing us with the POCT kits. We would also like to thank Prof. Dr. Alain Verstraete (Ghent University, Department of Clinical Chemistry, Microbiology and Immunology) for the interesting scientific discussions and his critical revision of the article.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Konikoff MR, Denson LA. Role of faecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524–34.10.1097/00054725-200606000-00013Search in Google Scholar
2. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.10.1016/S1590-8658(03)00381-5Search in Google Scholar
3. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817–26.10.1053/j.gastro.2010.11.058Search in Google Scholar PubMed PubMed Central
4. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010; 341:c3369.10.1136/bmj.c3369Search in Google Scholar PubMed PubMed Central
5. Keohane J, O’Mahony C, O’Mahony L, O’Mahony S, Quigley EM, Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation. Am J Gastroenterol 2010;105:1789–94.10.1038/ajg.2010.156Search in Google Scholar PubMed
6. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of faecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861–7.10.1373/49.6.861Search in Google Scholar PubMed
7. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.10.1053/gast.2000.8523Search in Google Scholar PubMed
8. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017–20.10.1080/00365520410007971Search in Google Scholar PubMed
9. Tibble JA, Bjarnason I. Faecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 2001;37:85–96.10.1358/dot.2001.37.2.614846Search in Google Scholar PubMed
10. Quantum Blue® Calprotectin Normal Range Quantitative Lateral Flow Assay LF-CAL20 package insert (2010-11-10).Search in Google Scholar
11. Quantum Blue® Calprotectin High Range Quantitative Lateral Flow Assay LF-CHR20 package insert (2011-04-11).Search in Google Scholar
12. Gisbert JP, McNicholl AG. Clinical review: questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56–66.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000263141300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.dld.2008.05.008Search in Google Scholar PubMed
13. Wassell J, Wallage M, Brewer E. Evaluation of the Quantum Blue rapid test for faecal calprotectin. Ann Clin Biochem 2012;49:55–8.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000299984500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
14. Dolci A, Panteghini M. Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin. Clin Chim Acta 2012;413:350–1.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000298462400065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1016/j.cca.2011.09.030Search in Google Scholar PubMed
15. Husebye E, Tøn H, Johne B. Biological variability of faecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96: 2683–7.Search in Google Scholar
16. Jensen MD, Kjeldsen J, Nathan T. Faecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol 2011;46:694–700.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000290492400007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.3109/00365521.2011.560680Search in Google Scholar PubMed
17. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Faecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008;68:343–7.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000257471700012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
18. Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, et al. Diagnostic performance of rapid tests for detection of faecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008;46:1275–80.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000259929300012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3Search in Google Scholar
19. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008;23:985–92.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000258884200010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f310.1007/s00384-008-0506-0Search in Google Scholar PubMed
20. Elkjaer M, Burisch J, Voxen Hansen V, Deibjerg Kristensen B, Slott Jensen JK. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 2010;31: 323–30.Search in Google Scholar
©2013 by Walter de Gruyter Berlin Boston
